
Renal Cell Carcinoma Clear Cell Variant with Chromophobe Differentiation -A Rare Case Presentation
Author(s) -
Tanvi Bhardwaj,
Kishore Hiwale,
Sunita Vagha
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i62b35896
Subject(s) - chromophobe cell , medicine , renal cell carcinoma , clear cell , nephrectomy , pathological , clear cell renal cell carcinoma , clear cell carcinoma , genitourinary system , pathology , kidney cancer , kidney , carcinoma
Renal Cell Carcinoma (RCC) is a diverse growth of various histological cell forms, as well as genetic, biological, and behavioral variations, accounting for around 2%-4% of all genitourinary cancers worldwide and having the highest mortality rate. RCC is a rare symptom that occurs from the lower pole of the left kidney. Histopathological testing is critical for diagnosis, staging, and treatment evaluation. As a consequence, proper surgical and pathological correlation is critical for the diagnosis of such an unusually presented RCC. As a result, various RCC variants should be considered for proper diagnosis. We are here presenting a case of a woman aged44-year-old, complaining for two months about a lump in her abdomen. Pain in the left lumbar area was noticed, which was progressive and accompanied by hematuria. The post-nephrectomy specimen was sent for histopathological analysis, and RCC was found (Clear Cell variant with chromophobe differentiation). RCC (a Clear cell variant with Chromophobe differentiation) is an unusual manifestation that arises from the left kidney's lower pole. In terms of diagnosis, staging, and treatment assessment, histopathological testing is crucial. As a result, for the diagnosis of such an unusually presented RCC, proper surgical and pathological correlation is essential. It's critical to acknowledge the presence of this clinical entity, which, though uncommon, may offer yet another reason to pursue surgical or immunological treatment for metastatic renal cancer. The finding will inspire & motivate researchers to pursue immunologic and other disease-related research.